VOICES FALL 2020
New York, NY | vellorecmc.org
of VELLORE
"I think India will have a big role in making SARS-Cov-2 vaccines for the world." - DR. PRIYA ABRAHAM Click here to watch the full interview with Dr. Abraham.
At the Forefront of the Fight Against COVID-19: Dr. Priya Abraham (Batch '81)
who are comfortable with whole genome sequencing. We've been able to look at 700 odd SARS-CoV-2 strains and have also generated about
I
n November 2019, just two months
Dr. Priya Abraham: Successfully isolating
before the first coronavirus case was
the virus in early March gave us the
detected in India, Dr. Priya Abraham
leverage to make our first indigenous
was appointed as the Director of the
ELISA (enzyme-linked immunosorbent
National Institute of Virology (NIV) in
assay), at a time when there were no
Pune, India. Since then, Dr. Abraham and
good serological assays.
her team have been actively engaged in
Another big benefit from our ability to
300 odd sequences to look at the profile of “clades” in our country. It was heartening to know that the real time polymerase chain reaction (PCR) assay that we put together was able to identify all these different varied strains, which meant it was robust enough as a
various aspects of the SARS-CoV-2 virus,
isolate and grow the virus was that we
diagnostic tool.
including diagnostic and vaccine-related
successfully propagated 11 or 12 strains
efforts.
in the laboratory - this contributed to
H: And have you been able to develop new rapid tests?
In an interview with Dr. Honorine
the development of a vaccine. We are
Ward (Batch ’69), Dr. Abraham discusses
working closely with Bharat Biotech on
NIV’s leading efforts in diagnostics and
a vaccine candidate. Apart from giving
vaccine development in India and her
them our strain, we have conducted
leadership at a prominent governmental
virus challenge experiments as part of
institution as a CMC alumna.
pre-clinical trials, which are essential to
Dr. Honorine Ward: You and your team at NIV were instrumental in isolating and sequencing one or more strains of the SARS-CoV-2 virus. How has this enabled NIV to work on developing diagnostics and vaccines for COVID-19?
vaccine development. With regard to sequencing, the first two sequences from India came out of the first three cases that were detected in this institute. I am privileged to work with great scientists
P: Right now, we do not have a rapid test, but we have developed a real time PCR Kit, where we have put together the probe, (continued on page 3) Dr. Ida B. Scudder Assisted Living Center On September 16th, the doors to the Center for retired CMC faculty and staff officially opened! Read more on page 4.